drugset / Trial / NCT04056065

PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock

NCT04056065 ↗

Phase 2 Completed 50 enrolled Pharmazz, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a prospective, multi-centric, randomized, double-blind, parallel, controlled phase-II efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock. Centhaquine is highly safe and well tolerated. Toxicological studies showed high safety margin in preclinical studies. Its safety and tolerability has been demonstrated in a human phase I study in 25 subjects (CTRI/2014/06/004647; NCT02408731).

Timeline

Start
2017-05-29
Primary completion
2018-09-19
Completion
2018-10-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Centhaquine Unknown 0.01 mg/kg Intravenous

Indications

No indication recorded.